| Cox Model (n = 329) . | Cumulative Incidence of Viremia . | ICU Discharge (CSHR) . | Death in ICU (CSHR) . | Death in ICU (SHR) . | Population-Attributable Fraction of ICU Mortality at Day 30 . |
|---|---|---|---|---|---|
| Individual viremia | |||||
| Cytomegalovirus | 60 (18) | 1.07 (0.77–1.49) | 1.61 (0.94–2.75) | 1.62 (0.80–3.25) | 0.12 (0.00–0.24) |
| Epstein–Barr virus | 157 (48) | 0.75 (0.57–0.98) | 1.18 (0.70–2.01) | 1.61 (0.88–2.92) | 0.25 (0.05–0.44) |
| Human herpesvirus 6 | 80 (24) | 0.80 (0.59–1.10) | 1.20 (0.71–2.03) | 1.41 (0.74–2.68) | 0.18 (0.04–0.42) |
| Herpes simplex virus type 1 | 87 (26) | 0.84 (0.63–1.12) | 1.22 (0.73–2.05) | 1.27 (0.65–2.49) | 0.09 (-0.05–0.22) |
| Herpes simplex virus type 2 | 13 (4) | NA | NA | NA | NA |
| Varicella zoster virus | 2 (1) | NA | NA | NA | NA |
| Multiple viremia | |||||
| ≥2 concurrent viremia events | 112 (34) | 0.79 (0.59–1.06) | 1.52 (0.91–2.52) | 1.90 (0.98–3.69) | 0.23 (0.07–0.40) |
| Cox Model (n = 329) . | Cumulative Incidence of Viremia . | ICU Discharge (CSHR) . | Death in ICU (CSHR) . | Death in ICU (SHR) . | Population-Attributable Fraction of ICU Mortality at Day 30 . |
|---|---|---|---|---|---|
| Individual viremia | |||||
| Cytomegalovirus | 60 (18) | 1.07 (0.77–1.49) | 1.61 (0.94–2.75) | 1.62 (0.80–3.25) | 0.12 (0.00–0.24) |
| Epstein–Barr virus | 157 (48) | 0.75 (0.57–0.98) | 1.18 (0.70–2.01) | 1.61 (0.88–2.92) | 0.25 (0.05–0.44) |
| Human herpesvirus 6 | 80 (24) | 0.80 (0.59–1.10) | 1.20 (0.71–2.03) | 1.41 (0.74–2.68) | 0.18 (0.04–0.42) |
| Herpes simplex virus type 1 | 87 (26) | 0.84 (0.63–1.12) | 1.22 (0.73–2.05) | 1.27 (0.65–2.49) | 0.09 (-0.05–0.22) |
| Herpes simplex virus type 2 | 13 (4) | NA | NA | NA | NA |
| Varicella zoster virus | 2 (1) | NA | NA | NA | NA |
| Multiple viremia | |||||
| ≥2 concurrent viremia events | 112 (34) | 0.79 (0.59–1.06) | 1.52 (0.91–2.52) | 1.90 (0.98–3.69) | 0.23 (0.07–0.40) |
Abbreviations: CSHR, cause-specific hazard ratio; ICU, intensive care unit; NA, not applicable, no multivariable analyses because of low number of events; SHR, Subdistribution Hazard Ratio.
Data are presented as absolute numbers (%) or hazard ratios with 95% confidence intervals. The hazard ratios are derived from multivariable models with adjustment for the time-varying onset of viremia and baseline differences at ICU admission, including Acute Physiology and Chronic Health Evaluation (APACHE) IV score, prior ICU admission during the hospital stay, surgical reason for admission, and Charlson comorbidity index.
CSHR estimates the direct effect of viremia on clinical outcome (ie, ICU discharge or death). The subdistribution hazard ratio is a summary measure of both separate cause-specific hazards and estimates the overall risk of dying from viremia while taking into account the competing event of discharge alive from the ICU.
| Cox Model (n = 329) . | Cumulative Incidence of Viremia . | ICU Discharge (CSHR) . | Death in ICU (CSHR) . | Death in ICU (SHR) . | Population-Attributable Fraction of ICU Mortality at Day 30 . |
|---|---|---|---|---|---|
| Individual viremia | |||||
| Cytomegalovirus | 60 (18) | 1.07 (0.77–1.49) | 1.61 (0.94–2.75) | 1.62 (0.80–3.25) | 0.12 (0.00–0.24) |
| Epstein–Barr virus | 157 (48) | 0.75 (0.57–0.98) | 1.18 (0.70–2.01) | 1.61 (0.88–2.92) | 0.25 (0.05–0.44) |
| Human herpesvirus 6 | 80 (24) | 0.80 (0.59–1.10) | 1.20 (0.71–2.03) | 1.41 (0.74–2.68) | 0.18 (0.04–0.42) |
| Herpes simplex virus type 1 | 87 (26) | 0.84 (0.63–1.12) | 1.22 (0.73–2.05) | 1.27 (0.65–2.49) | 0.09 (-0.05–0.22) |
| Herpes simplex virus type 2 | 13 (4) | NA | NA | NA | NA |
| Varicella zoster virus | 2 (1) | NA | NA | NA | NA |
| Multiple viremia | |||||
| ≥2 concurrent viremia events | 112 (34) | 0.79 (0.59–1.06) | 1.52 (0.91–2.52) | 1.90 (0.98–3.69) | 0.23 (0.07–0.40) |
| Cox Model (n = 329) . | Cumulative Incidence of Viremia . | ICU Discharge (CSHR) . | Death in ICU (CSHR) . | Death in ICU (SHR) . | Population-Attributable Fraction of ICU Mortality at Day 30 . |
|---|---|---|---|---|---|
| Individual viremia | |||||
| Cytomegalovirus | 60 (18) | 1.07 (0.77–1.49) | 1.61 (0.94–2.75) | 1.62 (0.80–3.25) | 0.12 (0.00–0.24) |
| Epstein–Barr virus | 157 (48) | 0.75 (0.57–0.98) | 1.18 (0.70–2.01) | 1.61 (0.88–2.92) | 0.25 (0.05–0.44) |
| Human herpesvirus 6 | 80 (24) | 0.80 (0.59–1.10) | 1.20 (0.71–2.03) | 1.41 (0.74–2.68) | 0.18 (0.04–0.42) |
| Herpes simplex virus type 1 | 87 (26) | 0.84 (0.63–1.12) | 1.22 (0.73–2.05) | 1.27 (0.65–2.49) | 0.09 (-0.05–0.22) |
| Herpes simplex virus type 2 | 13 (4) | NA | NA | NA | NA |
| Varicella zoster virus | 2 (1) | NA | NA | NA | NA |
| Multiple viremia | |||||
| ≥2 concurrent viremia events | 112 (34) | 0.79 (0.59–1.06) | 1.52 (0.91–2.52) | 1.90 (0.98–3.69) | 0.23 (0.07–0.40) |
Abbreviations: CSHR, cause-specific hazard ratio; ICU, intensive care unit; NA, not applicable, no multivariable analyses because of low number of events; SHR, Subdistribution Hazard Ratio.
Data are presented as absolute numbers (%) or hazard ratios with 95% confidence intervals. The hazard ratios are derived from multivariable models with adjustment for the time-varying onset of viremia and baseline differences at ICU admission, including Acute Physiology and Chronic Health Evaluation (APACHE) IV score, prior ICU admission during the hospital stay, surgical reason for admission, and Charlson comorbidity index.
CSHR estimates the direct effect of viremia on clinical outcome (ie, ICU discharge or death). The subdistribution hazard ratio is a summary measure of both separate cause-specific hazards and estimates the overall risk of dying from viremia while taking into account the competing event of discharge alive from the ICU.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
